Last updated: 2026-09-16 10:31:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Compugen Ltd (CGEN) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $2.46, with a market capitalisation of $234.93M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.30 to $3.24. This page covers its latest market performance, valuation, price trends and company information.
$234.93M | |
$2.42 | |
$19.90 | |
$0.34 | |
$2.41 | |
10.00 | |
280.88K | |
-- | |
$3.24 | |
$1.30 | |
-- | |
-- |
Compugen Ltd (CGEN) is trading at $2.46 in pre-market trading as of 2026-09-16 09:24:00, up 2.07% ($0.05) from the previous close of $2.41
Pre-market trading shows how investors are pricing CGEN before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Compugen Ltd (CGEN) moved from $2.59 to $2.46, representing a decline of 5.02% ($0.13).
The stock traded between $2.37 and $2.63 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 218.68 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 60.1%
CGEN is currently trading at $2.46, placing it 60.1% of the way from its 52-week low of $1.30 to its 52-week high of $3.24. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
| Employees | 75 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Compugen Ltd (CGEN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.